DDX21 Double Nickase Plasmid (h): sc-405770-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DDX21 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- DDX21 Double Nickase Plasmid (h) and DDX21 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting DDX21. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DDX21 Antibody (D-8): sc-376953
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DDX21 Double Nickase Plasmid (h) | sc-405770-NIC | 20 µg | $410.00 | |||
DDX21 Double Nickase Plasmid (h2) | sc-405770-NIC-2 | 20 µg | $410.00 |
DDX21 encodes a nucleolar DEAD-box RNA helicase that coordinates rRNA transcription and processing, ribosome biogenesis, and higher-order nucleolar organization. Through ATP-dependent remodeling of RNA–protein complexes, DDX21 contributes to RNA polymerase I–driven rDNA transcription, pre-rRNA maturation, and coupling of ribosome production to cellular growth programs. DDX21 has also been implicated in regulation of mRNA translation and innate immune signaling via interactions with RNA species and ribonucleoprotein assemblies. Dysregulation of nucleolar function and ribosome biogenesis pathways linked to DDX21 is associated with proliferative stress responses and altered gene expression programs observed across multiple disease contexts.
DDX21 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the DDX21 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within DDX21. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt DDX21 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of DDX21-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.